Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Items 201–300 of 869
Boisson, B., Quartier, P., & Casanova, J. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.005 · Cited by 77
Self-citationTreatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens
Kuemmerle-Deschner, J. B., Wittkowski, H., Tyrrell, P. N., Koetter, I., Lohse, P., Ummenhofer, K., Reess, F., Hansmann, S., Koitschev, A., Deuter, C., et al. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4237 · Cited by 79
“Canakinumab is reported to be well tolerated with no infusion-related adverse events and no formation of anticanakinumab antibodies [24].”
BackgroundResultInfluentialSelf-citationThe burgeoning field of innate immune‐mediated disease and autoinflammation
Peckham, D. G., Scambler, T., Savic, S., & McDermott, M. (2016) · The Journal of Pathology · doi:10.1002/path.4812 · Cited by 82
Brik, R., Butbul‐Aviel, Y., Lubin, S., Dayan, E. B., Minei, T. R., Tseng, L., & Hashkes, P. J. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38777 · Cited by 74
Mutation in the SLC29A3 Gene: A New Cause of a Monogenic, Autoinflammatory Condition
Melki, I., Lambot, K., Jonard, L., Couloigner, V., Quartier, P., Neven, B., & Bader‐Meunier, B. (2013) · PEDIATRICS · doi:10.1542/peds.2012-2255 · Cited by 74
Self-citationMalcová, H., Strizova, Z. O., Milota, T., Stříž, I., Šedivá, A., Cebecauerová, D., & Horváth, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.619257 · Cited by 76
“Interestingly, no injectionsite reactions were reported (35).”
Harrison, S. R., McGonagle, D., Nizam, S., Jarrett, S. J., van der Hilst, J. C. H., McDermott, M., & Savic, S. (2016) · JCI Insight · doi:10.1172/jci.insight.86336 · Cited by 77
“The cryopyrinopathies show rapid responses to IL-1 antagonism, with sustained efficacy (8– 12).”
Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome
Kuemmerle-Deschner, J. B., Hofer, F., Endres, T., Kortus-Goetze, B., Blank, N., Weißbarth‐Riedel, E., Schuetz, C., Kallinich, T., Krause, K., Rietschel, C., et al. (2015) · Rheumatology · doi:10.1093/rheumatology/kev416 · Cited by 78
Self-citationHansmann, S., Lainka, E., Horneff, G., Holzinger, D., Rieber, N. P., Jansson, A. F., Rösen‐Wolff, A., Erbis, G., Prelog, M., Brunner, J., et al. (2020) · Pediatric Rheumatology · doi:10.1186/s12969-020-0409-3 · Cited by 71
Self-citationLuís, J. P., Simões, C. J. V., & Brito, R. M. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031731 · Cited by 76
“Canakinumab Human IgG1 monoclonal antibody IL-1β Novartis CAPS 1 [226] TRAPS 1 [227] HIDS/MKD 1 [228] FMF 1 [229] Type 2 Diabetes [230] Still’s disease 1 [231] AD (NCT04795466) 2”
BackgroundMoltrasio, C., Romagnuolo, M., & Marzano, A. V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1007705 · Cited by 79
Federici, S., Martini, A., & Gattorno, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00351 · Cited by 73
“The first evidence for the efficacy of Canakinumab was obtained by a 48-week, double-blind, placebo-controlled, randomized withdrawal study, involving 35 MWS patients receiving a subcutaneous dose of 150 mg (or 2 mg/kg) every 8 weeks (18).”
MethodEvasion of inflammasome activation by microbial pathogens
Ulland, T. K., Ferguson, P. J., & Sutterwala, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75254 · Cited by 75
“These agents have been utilized to treat a number of inflammatory disorders, including CAPS (98, 100, 101), other monogenic autoinflammatory disorders (75), gout (102), type 1 diabetes (103), type 2 diabetes (104, 105), RA (106), sJIA (107), Schnitzler syndrome (108), and Behçet syndrome (109) as…”
Urticaria mimickers in children
Mathur, A. N., & Mathes, E. F. D. (2013) · Dermatologic Therapy · doi:10.1111/dth.12103 · Cited by 74
Inhibitor of apoptosis proteins in human health and disease
Hrdinka, M., & Yabal, M. (2019) · Genes and Immunity · doi:10.1038/s41435-019-0078-8 · Cited by 83
Calabrese, L., Fiocco, Z., Satoh, T. K., Peris, K., & French, L. E. (2022) · British Journal of Dermatology · doi:10.1111/bjd.20975 · Cited by 71
Lee, R., & Dick, A. D. (2011) · Eye · doi:10.1038/eye.2011.255 · Cited by 73
Hearing loss in Muckle‐Wells syndrome
Kuemmerle-Deschner, J. B., Koitschev, A., Ummenhofer, K., Hansmann, S., Plontke, S. K., Koitschev, C., Koetter, I., Angermair, E., & Benseler, S. M. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37810 · Cited by 73
Self-citationMonogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis
Henderson, C., & Goldbach‐Mansky, R. T. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32833ceff4 · Cited by 76
The fresco of autoinflammatory diseases from the pediatric perspective
Rigante, D. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.10.008 · Cited by 69
Rondeau, J., Ramage, P., Zurini, M. G. M., & Gram, H. (2015) · mAbs · doi:10.1080/19420862.2015.1081323 · Cited by 73
From bench to bedside and back again: translational research in autoinflammation
Holzinger, D., Kessel, C., Omenetti, A., & Gattorno, M. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.79 · Cited by 75
Chronic Infantile Neurological Cutaneous and Articular (CINCA) syndrome: a review
Finetti, M., Omenetti, A., Federici, S., Caorsi, R., & Gattorno, M. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0542-8 · Cited by 73
“Canakinumab is used subcutaneously at a starting dose of 150 mg (or 2 mg/kg) every 8 weeks [51].”
BackgroundA systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner
Rigante, D. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1280396 · Cited by 69
“More recently, canakinumab, a fully human anti-IL-1β monoclonal antibody that selectively blocks IL-1β with high affinity, which has a long plasma half-life of 21–28 days, has demonstrated a prompt and sustained clinical efficacy when administered subcutaneously every 4–8 weeks in CAPS patients by neutralization of ex…”
BackgroundUpdate on biologicals for treatment of juvenile idiopathic arthritis
Horneff, G. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.735657 · Cited by 68
“Its efficacy in the treatment of genetic fever syndromes makes canakinumab an interesting option for use in systemic arthritis [68].”
BackgroundSystemic autoinflammatory disease in adults
Betrains, A., Staels, F., Schrijvers, R., Meyts, I., Humblet‐Baron, S., Langhe, E. D., Wouters, C. H., Blockmans, D., & Vanderschueren, S. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102774 · Cited by 74
Rigante, D., Frediani, B., Galeazzi, M., & Cantarini, L. (2013) · BioMed Research International · doi:10.1155/2013/485103 · Cited by 68
“Anakinra, the recombinant IL-1 receptor antagonist, was the first biologic designed for the selective blockage of IL-1 [39], while canakinumab, a fully human monoclonal anti-IL-1beta antibody, has recently been registered for patients with CAPS, though the optimal administration schedule in terms of dosage and frequen…”
BackgroundWittkowski, H., Kuemmerle-Deschner, J. B., Austermann, J., Holzinger, D., Goldbach‐Mansky, R. T., Gramlich, K., Lohse, P., Jung, T., Roth, J., Benseler, S. M., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.152496 · Cited by 72
Self-citationBrachat, A., Grom, A. A., Wulffraat, N. M., Brunner, H. I., Quartier, P., Brik, R., McCann, L. J., Özdoğan, H., Rutkowska‐Sak, L., Schneider, R., et al. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1212-x · Cited by 68
“IL-1β, thereby inactivating IL-1β signaling pathways and neutralizing its downstream effects [16, 17].”
Self-citationMetabolic regulation of inflammasomes in inflammation
Yang, Q., Liu, R., Yu, Q., Bi, Y., & Liu, G. (2019) · Immunology · doi:10.1111/imm.13056 · Cited by 73
The hereditary autoinflammatory disorders uncovered
Rigante, D., Vitale, A., Lucherini, O. M., & Cantarini, L. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.08.001 · Cited by 72
The role of NLRP3 inflammasome in infection-related, immune-mediated and autoimmune skin diseases
Wang, D., Duncan, B. C., Li, X., & Shi, J. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2020.03.001 · Cited by 71
A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease
Sibley, C. H., Chioato, A., Felix, S. D., Colin, L., Chakraborty, A., Plass, N., Rodriguez‐Smith, J., Brewer, C. C., King, K. A., Zalewski, C. K., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204877 · Cited by 71
Abajian, M., Młynek, A., & Maurer, M. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0269-0 · Cited by 67
Caorsi, R., Lepore, L., Zulian, F., Alessio, M., Stabile, A., Insalaco, A., Finetti, M., Battagliese, A., Martini, G., Bibalo, C., et al. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4184 · Cited by 67
“Other IL-1 inhibitors, such as rilonacept, a human dimeric fusion protein that incorporates the extra-cellular domain of both IL-1 receptor type I and IL-1 receptor accessory protein [14], and a fully human anti-IL-1b monoclonal antibody, canakinumab are also available [15].”
BackgroundLicensing Adaptive Immunity by NOD-Like Receptors
Liu, D., Rhebergen, A. M., & Eisenbarth, S. C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00486 · Cited by 72
“In fact, these disorders are now successfully treated by blocking IL-1β activity (166).”
BackgroundBiologic drugs in autoinflammatory syndromes
Caorsi, R., Federici, S., & Gattorno, M. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.027 · Cited by 65
“Majeed's syndrome (the anti-IL-1 monoclonal antibodies) [19–21] and rilonacept (IL1‐ TRAP) [22,23].”
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker, P. M. (2013) · Europe PMC (PubMed Central) · Cited by 86
Kolivras, A., Theunis, A., Ferster, A., Lipsker, D. M., Saß, U., Dussart, A., & André, J. (2010) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2010.01638.x · Cited by 64
Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians
Kuemmerle-Deschner, J. B., & Haug, I. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13502629 · Cited by 66
Self-citationRowczenio, D. M., Trojer, H., Russell, T., Baginska, A., Lane, T., Stewart, N. M., Gillmore, J. D., Hawkins, P. N., Woo, P. M., Mikołuć, B., et al. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4171 · Cited by 67
Self-citationFellmann, F., Angelini, F., Wassenberg, J., Perreau, M., Arenas-Ramirez, N., Simon, G., Boyman, O., Demaria, O., Christen‐Zaech, S., Hohl, D., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.053 · Cited by 63
Bridging the Gap between the Clinician and the Patient with Cryopyrin-Associated Periodic Syndromes
Cantarini, L., Lucherini, O. M., Frediani, B., Brizi, M. G., Bartolomei, B., Cimaz, R., Galeazzi, M., & Rigante, D. (2011) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201102400402 · Cited by 63
Savic, S., Dickie, L. J., Wittmann, M., & McDermott, M. (2012) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.07.009 · Cited by 70
Rigante, D. (2010) · PubMed · Cited by 61
Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment
Havnaer, A. G., & Han, G. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00440-y · Cited by 68
“Of note, the real-life effectiveness of canakinumab may be significantly lower than that in clinical trials—a 2016 study showed a real-life complete response rate of 72% [68], versus up to 97% reported in clinical trials [63], reflecting the importance of a treat-to-target approach and dose escalation based on individ…”
BackgroundKuemmerle-Deschner, J. B., Lohse, P., Koetter, I., Dannecker, G. E., Reess, F., Ummenhofer, K., Koch, S., Tzaribachev, N., Bialkowski, A., & Benseler, S. M. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3526 · Cited by 61
“With the advent of IL-1 inhibitors, such as Anakinra, Rilonacept and Canakinumab, successful treatment of patients with CAPS has for the first time become feasible [9-11].”
Self-citationIL-1β Biological Treatment of Familial Mediterranean Fever
Soriano, A., Verrecchia, E., Afeltra, A., Landolfi, R., & Manna, R. (2013) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-013-8358-y · Cited by 62
Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes
Spohn, G., Schori, C., Keller, I., Sladko, K., Sina, C., Guler, R., Schwarz, K., Johansen, P., Jennings, G. T., & Bachmann, M. F. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.48 · Cited by 63
Crittenden, D. B., & Pillinger, M. H. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-080911-105830 · Cited by 59
Regulation of interleukin 1α secretion by inflammasomes
Yazdi, A. S., & Drexler, S. K. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202252 · Cited by 67
Activation and Pharmacological Regulation of Inflammasomes
Chen, C., & Xu, P. (2022) · Biomolecules · doi:10.3390/biom12071005 · Cited by 60
“The FDA has approved three biologics, including the IL-1β receptor antagonist anakinra [221] and the neutraliz tion IL-1β antibodies canakinumab [222] and rilonacept [223].”
DAMPs in immunosenescence and cancer
Chen, F., Tang, H., Cai, X., Lin, J., Kang, R., Tang, D., & Liu, J. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.09.005 · Cited by 67
Aróstegui, J. I., Antón, J., Penadés, I. C., Robles‐Marhuenda, Á., Iglesias, E., López‐Montesinos, B., Banchereau, R., Hong, S., Joubert, Y., Junge, G., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40146 · Cited by 59
The Inflammasomes in Autoinflammatory Diseases with Skin Involvement
Beer, H., Contassot, E., & French, L. E. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.76 · Cited by 61
“In accordance with the pathogenetic role of IL-1b in CAPS, IL-1 inhibitors are extremely successful for their treatment (Hoffman et al., 2004, 2008; Lachmann et al., 2009; Kone-Paut et al., 2011).”
BackgroundEarly detection of sensorineural hearing loss in Muckle-Wells-syndrome
Kuemmerle-Deschner, J. B., Koitschev, A., Tyrrell, P. N., Plontke, S. K., Deschner, N., Hansmann, S., Ummenhofer, K., Lohse, P., Koitschev, C., & Benseler, S. M. (2015) · Pediatric Rheumatology · doi:10.1186/s12969-015-0041-9 · Cited by 59
“MWS treatment options include anakinra [17], a short acting IL-1 receptor antagonist and canakinumab, a fully human monoclonal antibody providing selective and prolonged IL-1β blockade [21] and rilonacept, an IL-1 trap fusion protein [16].”
BackgroundSelf-citationGiacomelli, R., Ruscitti, P., Alvaro, S., Ciccia, F., Liakouli, V., Benedetto, P. D., Guggino, G., Berardicurti, O., Carubbi, F., Triolo, G., et al. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1168293 · Cited by 57
What do we know about the inflammasome in humans?
Amin, J., Boche, D., & Rakić, S. (2016) · Brain Pathology · doi:10.1111/bpa.12479 · Cited by 60
“Specifically, antibody mediated inhibition of IL1b has been trialed in CAPS with two drugs now approved by the US Food and Drug Administration, following successful randomized controlled trials of Rilonacept (20) and Canakinumab (40).”
MethodAutoinflammatory Diseases in Childhood
Yıldız, M., Haşlak, F., Adroviç, A., Barut, K., & Kasapçopur, Ö. (2020) · Balkan Medical Journal · doi:10.4274/balkanmedj.galenos.2020.2020.4.82 · Cited by 75
“Gain-of-function mutations in NLRP3 (CIAS1) gene encoding cryopyrin protein are responsible for CAPS (81).”
BackgroundInfluentialRitter, M., Straubinger, K., Schmidt, S., Busch, D. H., Hagner, S., Garn, H., da Costa, C. P., & Layland, L. E. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12400 · Cited by 59
Issafras, H., Corbin, J., Goldfine, I. D., & Roell, M. K. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.205443 · Cited by 58
Mitroulis, I., Skendros, P., Oikonomou, A., Tzioufas, A. G., & Ritis, K. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146878 · Cited by 55
“Treatment with canakinumab (ACZ885, Ilaris; Novartis Pharma, Basel, Switzerland), a fully humanised monoclonal antibody targeting interleukin (IL)-1β,”
A Comprehensive Overview of the Hereditary Periodic Fever Syndromes
Rigante, D., Frediani, B., & Cantarini, L. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8537-8 · Cited by 55
“While canakinumab is known to neutralize IL-1β by competing for binding to IL-1 receptor, which blocks signaling by the antigen-antibody complex, gevokizumab, another recombinant humanized anti-IL-1β monoclonal antibody, should act as a regulatory antibody by altering the electrostatic surface of IL-1β itself [58].”
BackgroundAutoinflammatory Skin Disorders: The Inflammasome in Focus
Gurung, P., & Kanneganti, T. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.05.003 · Cited by 58
“More recent human studies have used Canakinumab (Ilaris®, Novartis), a human anti-IL-1b antibody specifically targeting IL-1b [32] to treat CAPS.”
InfluentialRomano, M., Arıcı, Z. S., Piskin, D., Alehashemi, S., Aletaha, D., Barron, K. S., Benseler, S. M., Berard, R. A., Broderick, L., Dedeoğlu, F., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42139 · Cited by 59
Self-citationBiological treatment in adult-onset Still's disease
Pouchot, J., & Arlet, J. (2012) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.07.002 · Cited by 57
Monogenic Autoinflammatory Diseases
Sanchez, G. A. M., de Jesus, A. A., & Goldbach‐Mansky, R. T. (2013) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2013.08.001 · Cited by 61
“The rapid improvement in clinical and laboratory parameters and safety data in all CAPS patients, led to the FDA approval of three anti-IL-1 agents for the treatment of CAPS: the long acting IL-1 inhibitors rilonacept (49, 50) and canakinumab (51), and the short acting IL-1 receptor antagonist anakinra (47) in the US,…”
BackgroundStackowicz, J., Gaudenzio, N., Serhan, N., Conde, E., Godon, O., Marichal, T., Starkl, P. M., Balbino, B., Roers, A., Bruhns, P., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201466 · Cited by 54
Biologics in children’s autoimmune disorders: efficacy and safety
Breda, L., Torto, M. D., Sanctis, S. D., & Chiarelli, F. (2010) · European Journal of Pediatrics · doi:10.1007/s00431-010-1238-z · Cited by 57
Howard, C., Noe, A., Skerjanec, A., Holzhauer, B., Wernsing, M., Ligueros-Saylan, M., & Thuren, T. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-94 · Cited by 52
Hyperuricaemia and gout: state of the art and future perspectives
Dalbeth, N., & So, A. K.-L. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.136218 · Cited by 52
“This was confirmed by the results of treatment with IL-1 inhibitors, which effectively controlled the signs and symptoms of the disease.”
ResultSuh, H. Y., Peck, C., Yu, K.-S., & Lee, H. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s121520 · Cited by 51
Sheng, C. C., Sahoo, D. H., Dugar, S. P., Prada, R. A., Wang, T. K. M., Hassan, O. K. A., Brennan, D. M., Culver, D. A., Rajendram, P., Duggal, A., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23451 · Cited by 57
Research progress on the NLRP3 inflammasome and its role in the central nervous system
Liu, S., Mi, W., & Wang, Y. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1328-9 · Cited by 55
Brogan, P. A., Hofer, M., Kuemmerle-Deschner, J. B., Koné‐Paut, I., Roesler, J., Kallinich, T., Horneff, G., Penadés, I. C., Sevilla‐Perez, B., Goffin, L., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41004 · Cited by 51
Self-citationRoles of Inflammasomes in Inflammatory Kidney Diseases
Fan, J., Xie, K., Wang, L., Zheng, N., & Yu, X. (2019) · Mediators of Inflammation · doi:10.1155/2019/2923072 · Cited by 53
“AIM2: Absent in melanoma 2 AKI: Acute kidney injury ALR: AIM2-like receptor ASC: Apoptosis-associated speck-like protein containing a CARD CAPS: Cryopyrin-associated periodic syndrome CARD: Caspase activation and recruitment domain CKD: Chronic kidney disease DAMPs: Damage-associated molecular patterns DN: Diabetic ne…”
BackgroundAnakinra for cryopyrin-associated periodic syndrome
Koné‐Paut, I., & Galeotti, C. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.861325 · Cited by 51
Deza, G., Brasileiro, A., Bertolín‐Colilla, M., Curto‐Barredo, L., Pujol, R. M., & Giménez‐Arnau, A. M. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.06.017 · Cited by 55
Balance between Interleukin-18 and Interleukin-18 binding protein in auto-inflammatory diseases
Harel, M., Fauteux‐Daniel, S., Girard-Guyonvarc'h, C., & Gabay, C. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155781 · Cited by 52
Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes
Koné‐Paut, I., & Piram, M. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.07.026 · Cited by 52
The NLRP3 inflammasome, a target for therapy in diverse disease states
Cook, G. P., Savic, S., Wittmann, M., & McDermott, M. (2010) · European Journal of Immunology · doi:10.1002/eji.200940162 · Cited by 53
Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome
de Koning, H. D., Schalkwijk, J., van der Meer, J. W. M., & Simon, A. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.023 · Cited by 50
Federici, S., Caorsi, R., & Gattorno, M. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13602 · Cited by 52
Lazaros, G. A., Antonatou, K., & Vassilopoulos, D. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00078 · Cited by 49
Sağ, E., Akal, F., Atalay, E., Akça, Ü. K., Demir, S., Demirel, D., Batu, E. D., Bilginer, Y., & Özen, S. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa121 · Cited by 49
Sun, H., Van, L. M., Floch, D., Jiang, X., Klein, U. R., Abrams, K. B., & Sunkara, G. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.754 · Cited by 48
Canakinumab for the treatment of familial Mediterranean fever
Özdoğan, H., & Uğurlu, S. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1313116 · Cited by 54
“One of the results of this registry was the continued effectiveness of canakinumab in CAPS patients for up to 5 years.”
BackgroundResultInfluentialThe role of mast cells in autoinflammation
Bonnekoh, H., Scheffel, J., Kambe, N., & Krause, K. (2018) · Immunological Reviews · doi:10.1111/imr.12633 · Cited by 52
The use of biologics and small molecules in pregnant patients with rheumatic diseases
Gerosa, M., Argolini, L. M., Artusi, C., & Chighizola, C. B. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1525293 · Cited by 48
Targeting cytokines to treat autoinflammatory diseases
Hausmann, J. S. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.10.016 · Cited by 53
Henderson, C., & Goldbach‐Mansky, R. T. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.02.013 · Cited by 51
“All patients show rapid improvement in clinical and laboratory parameters with treatment [62-67].”
Current perspectives on the interleukin‐1 family as targets for inflammatory disease
Hernandez-Santana, Y., Giannoudaki, E., León, G., Lucitt, M. B., & Walsh, P. T. (2019) · European Journal of Immunology · doi:10.1002/eji.201848056 · Cited by 48
The Role of NLRP3 Inflammasome in Pneumococcal Infections
Surabhi, S., Cuypers, F., Hammerschmidt, S., & Siemens, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.614801 · Cited by 50
Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)
McDermott, M., & Gillespie, J. (2010) · Journal of Inflammation Research · doi:10.2147/jir.s8109 · Cited by 51
“Due to the initial success of anakinra and subsequent studies further supporting the clinical efficacy of IL-1 treatment for FCAS and MWS, 21–23 progress has been made with the development of novel selective IL-1 biologics.”
Cryopyrin-associated periodic syndromes: background and therapeutics
Kubota, T., & Koike, R. (2010) · Modern Rheumatology · doi:10.1007/s10165-009-0271-0 · Cited by 49
Scarpioni, R., Rigante, D., Cantarini, L., Ricardi, M., Albertazzi, V., Melfa, L., & Lazzaro, A. (2014) · Clinical Rheumatology · doi:10.1007/s10067-013-2481-2 · Cited by 47
Church, L. D., & McDermott, M. (2010) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.66 · Cited by 46
Nidorf, S. M., Eikelboom, J. W., & Thompson, P. L. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413499972 · Cited by 49
“Canakinumab has been approved for the treatment of 2 rare immune disorders including periodic syndrome(96) and familial cold autoinflammatory syndrome.(97) Canakinumab has been trialed in rheumatoid arthritis and systemic-onset juvenile idiopathic arthritis with some success and has been extensively studied for the tr…”
BackgroundIsoda, K., Akita, K., Kitamura, K., Sato-Okabayashi, Y., Kadoguchi, T., Isobe, S., Ohtomo, F., Sano, M., Shimada, K., Iwakura, Y., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.05.072 · Cited by 46
Canonical and non-canonical functions of NLRP3
Accogli, T., Hibos, C., & Végran, F. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.01.001 · Cited by 51
“Based on the success of Ana-kinra treatment, new therapies inhibiting IL-1-mediated inflam-mation have been developed successfully, such as Rilonacept, a dimeric IL-1 receptor fusion, approved by the FDA in 2008, or Cana-kinumab, an anti-IL-1 monoclonal antibody approved in 2009 [107–108].”
Method
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.